Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 11, 2026
Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge?
View original at finance.yahoo.com“For AstraZeneca, the latest twelve month Free Cash Flow (FCF) is about US$9.49b. ... AZN Discounted Cash Flow as at Apr 2026”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The DCF model arrives at an estimated intrinsic value of US$238.68 per share for AstraZeneca
60% confidenceAstraZeneca's DCF analysis suggests the stock is undervalued by 36.2%
60% confidenceAstraZeneca has a valuation score of 3 out of 6
60% confidence
Data points we hold from this source
| AstraZeneca AB · stock return 30day | 5.2 percent |
| AstraZeneca AB · stock return 1year | 54.8 percent |
| AstraZeneca AB · free cash flow | 9.49 USD |
| AstraZeneca AB · stock return ytd | 12.1 percent |
| AstraZeneca AB · projected free cash flow | 20.16 USD |
| AstraZeneca AB · valuation score | 3 out_of_6 |
| AstraZeneca AB · intrinsic value dcf | 238.68 USD |
| AstraZeneca AB · stock return 7day | -0.6 percent |